Blood‐based biomarkers and risk of MCI symptom onset over the short and long‐term

Background Blood‐based biomarkers of amyloid and tau have been shown to predict AD‐dementia risk. Much less is known about their ability to predict risk of Mild Cognitive Impairment (MCI) among cognitively normal individuals. It is also unclear how AD non‐specific blood markers of neurodegeneration and neuroinflammation predict MCI and whether they add predictive power above and beyond AD biomarkers. The current study examined whether levels of blood biomarkers of amyloid (Ab42/Ab40), tau (p‐tau181), neurodegeneration (NfL), and neuroinflammation (GFAP, YKL40, sTREM2) collected when participants were cognitively normal predict the time to onset of MCI, both alone and in combination. Method The plasma assays were based on the NeuroToolKit (cobas Elecsys assays, Roche Diagnostics) and obtained from 271 cognitively unimpaired BIOCARD Study participants at their initial baseline evaluation (mean age=57.5y, including 82 who progressed to MCI/dementia). A second ‘baseline’ specimen (collected using different procedures) was evaluated for a subset of participants who were cognitively normal ∼7 years later (N=202) (mean age = 64.5y), including 31 who later developed MCI/dementia, Table 1). Mean clinical follow‐up was 15.5 years for Baseline 1 and 9.9 years for ‘Baseline 2’. Cox regression models tested the association of biomarker levels with time to MCI symptom onset, separately for both baselines. Results For both baselines, lower levels of Ab42/Ab40, higher GFAP, and a higher ratio of p‐tau181/Ab42/Ab40were each associated with an earlier time to MCI symptom onset (p’s